Metformina Tevagen (Metformin)

Metformin reduces hepatic glucose production, decreases intestinal glucose absorption, and enhances peripheral insulin sensitivity. These actions are mediated mainly through activation of AMP‑activated protein kinase (AMPK), which helps lower circulating glucose without stimulating insulin release.

The specific dose of Metformina Tevagen is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Metformina Tevagen is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy when benefits outweigh risks, but clinicians should evaluate each case. Breastfeeding mothers should discuss potential exposure with their doctor.

To request Metformina Tevagen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformin is often first‑line therapy for type 2 diabetes because it improves insulin sensitivity without causing weight gain and has a low risk of hypoglycaemia when used alone. Compared with sulfonylureas or insulin, metformin does not stimulate insulin release, making it safer in many patients, though combination therapy may be needed for optimal control.

Metformina Tevagen should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not store in humid or excessively hot environments.

Metformina Tevagen is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets (or other oral form) should be swallowed whole with a full glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, hypoxia, or excessive alcohol intake. Other serious concerns include severe hypoglycaemia when combined with insulin or secretagogues, and rare cases of hepatic dysfunction.

Metformina Tevagen is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, or in those with conditions that predispose to hypoxia such as severe heart failure or recent myocardial infarction.